MiRNA-mediated EMT and CSCs in cancer chemoresistance

Dong, Bing; Li, Shiyu; Zhu, Shuangli; Yi, Ming; Luo, Suxia; Wu, Kongming

doi:10.1186/s40164-021-00206-5

Cited by 54 publications

(39 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The manipulation of miRNA expression may represent a means of inhibiting EMT-mediated resistance to chemotherapy agents. Compared to the permanent impact of mutations and deletions, the expression of miRNAs and EMT-ATFs can be dynamically regulated, making them attractive targets for personalized oncological treatment [ 195 ]. As chemotherapy usually targets a single oncogenic signal and is therefore inevitably associated with the development of resistance or recurrence, multiple simultaneous approaches to various pathways and cancer cell traits may yield better results [ 196 ].…”

Section: Discussionmentioning

confidence: 99%

Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition

et al. 2021

View full text Add to dashboard Cite

The increasing incidence of resistance to chemotherapeutic agents has become a major issue in the treatment of oral cancer (OC). Epithelial-mesenchymal transition (EMT) has attracted a great deal of attention in recent years with regard to its relation to the mechanism of chemotherapy drug resistance. EMT-activating transcription factors (EMT-ATFs), such as Snail, TWIST, and ZEB, can activate several different molecular pathways, e.g., PI3K/AKT, NF-κB, and TGF-β. In contrast, the activated oncological signal pathways provide reciprocal feedback that affects the expression of EMT-ATFs, resulting in a peritumoral extracellular environment conducive to cancer cell survival and evasion of the immune system, leading to resistance to multiple chemotherapeutic agents. We present an overview of evidence-based chemotherapy for OC treatment based on the National Comprehensive Cancer Network (NCCN) Chemotherapy Order Templates. We focus on the molecular pathways involved in drug resistance related to the EMT and highlight the signal pathways and transcription factors that may be important for EMT-regulated drug resistance. Rapid progress in antitumor regimens, together with the application of powerful techniques such as high-throughput screening and microRNA technology, will facilitate the development of therapeutic strategies to augment chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition

et al. 2021

View full text Add to dashboard Cite

show abstract

“…109,113 An increasing number of miRNAs have been shown to mediate proliferation, EMT, and cancer stemness through diverse targets. 104 For example, Le et al 114 demonstrated that MVs derived from murine and human breast cancer cells could be used to deliver miR-200 to nonmetastatic cancer cells, promoting mesenchymal-to-epithelial transition. Tumors expressing miR-200 and MVs from murine cancer and human xenograft models facilitated metastasis of poorly metastatic cells at both nearby and distant sites, and endowed these cells with the ability to colonize distant tissues in a miR-200-dependent manner.…”

Section: Dovepressmentioning

confidence: 99%

Roles of Microvesicles in Tumor Progression and Clinical Applications

Zhu¹,

Li²,

Yi³

et al. 2021

IJN

Self Cite

View full text Add to dashboard Cite

Microvesicles are extracellular vesicles with diameter ranging from 100 to 1000 nm that are secreted by tumor cells or other cells in the tumor microenvironment. A growing number of studies demonstrate that tumor-derived microvesicles are involved in tumor initiation and progression, as well as drug resistance. In addition, tumor-derived microvesicles carry a variety of immunogenic molecules and inhibit tumor response to immunotherapy; therefore, they can be exploited for use in tumor vaccines. Moreover, because of their high stability, tumor-derived microvesicles extracted from body fluids can be used as biomarkers for cancer diagnosis or assessment of prognosis. Tumor-derived microvesicles can also be deployed to reverse drug resistance of tumor regenerative cells, or to deliver chemotherapeutic drugs and oncolytic adenovirus for the treatment of cancer patients. This review summarizes the general characteristics of tumor-derived microvesicles, focusing on their biological characteristics, their involvement in tumor progression, and their clinical applications.

show abstract

“…Non-coding RNAs (ncRNAs), including miRNAs exert critical function in the regulation of cellular processes that are involved in the EMT, as a result, some miRNAs impact cancer stemness and drug resistance. Therefore, understanding the relationship between EMT and miRNAs is beneficial to both basic research and clinical treatment [ 81 , 82 , 83 , 84 ]. The impact of VPA on miR-34a [ 85 ], miR-520h [ 81 ], and their target gene HDAC1 expression, as well as their involvement in the induction of apoptosis in MCF-7 and MDA-MB-231 BC cell lines, were evaluated.…”

Section: Valproic Acid and Breast Cancermentioning

confidence: 99%

Valproic Acid and Breast Cancer: State of the Art in 2021

Wawruszak

Hałasa

Okon

et al. 2021

Cancers

View full text Add to dashboard Cite

Valproic acid (2-propylpentanoic acid, VPA) is a short-chain fatty acid, a member of the group of histone deacetylase inhibitors (HDIs). VPA has been successfully used in the treatment of epilepsy, bipolar disorders, and schizophrenia for over 50 years. Numerous in vitro and in vivo pre-clinical studies suggest that this well-known anticonvulsant drug significantly inhibits cancer cell proliferation by modulating multiple signaling pathways. Breast cancer (BC) is the most common malignancy affecting women worldwide. Despite significant progress in the treatment of BC, serious adverse effects, high toxicity to normal cells, and the occurrence of multi-drug resistance (MDR) still limit the effective therapy of BC patients. Thus, new agents which improve the effectiveness of currently used methods, decrease the emergence of MDR, and increase disease-free survival are highly needed. This review focuses on in vitro and in vivo experimental data on VPA, applied individually or in combination with other anti-cancer agents, in the treatment of different histological subtypes of BC.

show abstract

MiRNA-mediated EMT and CSCs in cancer chemoresistance

Cited by 54 publications

References 129 publications

Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition

Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition

Roles of Microvesicles in Tumor Progression and Clinical Applications

Valproic Acid and Breast Cancer: State of the Art in 2021

Contact Info

Product

Resources

About